垂体腺瘤 (PA) 占颅内肿瘤的 10-20%，分为功能性和无功能性，并根据大小进一步划分。无功能的肿瘤会引起机械症状，而有功能的肿瘤会导致激素分泌过多综合征。初始治疗包括手术和泌乳素瘤的药物治疗。放射治疗（RT）被用作辅助治疗，采用多种方式，包括传统、立体定向放射外科（SRS）和分段立体定向放射外科（FSRT）。尽管有效，但放疗与并发症和毒性有关，例如垂体功能减退、视神经炎、继发性中枢神经系统肿瘤和神经认知缺陷。描述放射治疗作为功能性 PA 治疗的死亡率信息。对 2000 年至 2017 年的 PubMed 搜索进行了以下文章：传统 RT 需要多次进行高能辐射，而 SRS 在单次治疗中提供精确的高剂量。 FSRT 使用线性加速器提供更高的精度，提供多个剂量。视神经结构的接近度和肿瘤体积决定了 RT 方式。研究表明，SRS 和 FSRT 在肿瘤和内分泌控制方面具有功效，但风险和并发症各不相同。已经对接受放疗治疗的垂体腺瘤的死亡率进行了评估，揭示了其复杂性。肢端肥大症与脑血管疾病死亡率增加相关，可能由放疗引起。无功能垂体大腺瘤的放射也会增加脑血管风险，而放射治疗引起的垂体功能低下与心血管死亡率增加有关。放疗引起的损伤归因于微血管病变和小动脉变化。现代技术可减轻并发症，虽然更安全，但仍需要长期研究。多学科评估指导治疗决策，优化疗效并最大程度降低风险，最终改善患者的生活质量。版权所有 © 2023 Instituto Mexicano del Seguro Social (IMSS)。由爱思唯尔公司出版。保留所有权利。

Pituitary adenomas (PA), comprising 10-20% of intracranial tumors, are classified as functioning and non-functioning and are further divided by size. Non-functioning tumors cause mechanical symptoms while functioning ones result in hormonal hypersecretion syndromes. Initial treatment involves surgery, with medical treatment for prolactinomas. Radiotherapy (RT) is employed as an adjuvant treatment, with various modalities including conventional, stereotactic radiosurgery (SRS), and fractionated stereotactic RT (FSRT). Although effective, RT is associated with complications and toxicities such as hypopituitarism, optic neuritis, secondary CNS tumors, and neurocognitive deficits.Describe the information on mortality from radiotherapy as treatment of functioning PA.A PubMed search spanning 2000-2017 was conducted for articles on pituitary RT.Conventional RT entails high-energy radiation over multiple sessions, while SRS delivers precise high doses in a single session. FSRT offers enhanced precision using a linear accelerator, delivering multiple doses. Optic structure proximity and tumor volume dictate RT modality. Studies have shown SRS and FSRT's efficacy in tumor and endocrine control, with variable risks and complications. Mortality rates in pituitary adenomas treated with RT have been evaluated, revealing complexities. Acromegaly, associated with increased mortality due to cerebrovascular disease, may result from RT. Irradiation of non-functioning pituitary macroadenomas also elevates cerebrovascular risk, while radiotherapy-induced hypopituitarism is associated with increased cardiovascular mortality. RT-induced damage is attributed to microvascular lesions and arteriolar changes.Modern techniques mitigate complications, and although safer, long-term studies are needed. Multidisciplinary evaluation guides the treatment decision, optimizing efficacy and minimizing risk, ultimately improving the patient's quality of life.Copyright © 2023 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights reserved.